[State of the hypothalamo-hypophyseal-ovarian system in young nullipara women with ectopia of the cervix of uterus during taking the hormonal contraceptives].
Background diseases of the cervix of the uterus play one of the leading roles in the structure of gynecological pathology and present the risk of the development precancerous changes. Ectopia is observed in the structure of precancerous processes of the cervix of the uterus in 38, 8% of women and in 42, 2% cases of gynecological diseases. Our aim is to investigate the content of gonadotropic and steroid hormones in the blood plasma of young nullipara women with different types of ectopia during taking hormonal contraceptives. Cohort study has been carried out by using simple blind method. The quantitative data analyses were performed using the Statistical Package for the Social Sciences (SPSS) in order to reveal the correlation between taking of oral hormonal contraceptives and the hormone content in the blood plasma among young nullipara women with different types of ectopia. Descriptive statistics were calculated for all the study variables. The results displayed correlation between taking the oral hormonal contraceptives and changes of hormonal background in young women with ectopia of the cervix of the uterus during taking hormonal contraceptives. The study show that the secretions of gonadotropic hormone and ovary hormone peculiarities depend on the type of ectopia of the cervix of the uterus. The effect of hormonal contraception on cervix of the uterus of young nullipara women with ectopia was investigated. The oral contraceptive, Exluton is recommended in young nullipara women with ectopia.
Djangidze
M
M
Tbilisi State Medical University, Department of Obstetrics and Gynecology.
Djugeli
M
M
Museridze
N
N
Zakaraia
L
L
D000293:Adolescent; D000328:Adult; D003127:Colposcopy / Q000379:methods; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000494:pharmacology*; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage / Q000494:pharmacology*; D017135:Desogestrel / Q000008:administration & dosage / Q000494:pharmacology*; D019304:Ethinyl Estradiol-Norgestrel Combination / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000503:physiopathology*; D008234:Lynestrenol / Q000008:administration & dosage / Q000494:pharmacology*; D010053:Ovary / Q000187:drug effects* / Q000503:physiopathology*; D010298:Parity; D011247:Pregnancy; D002578:Uterine Cervical Dysplasia / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology*
D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D019304:Ethinyl Estradiol-Norgestrel Combination; D017135:Desogestrel; D008234:Lynestrenol